When two or more
medicines are taken together, it can change how the medicines work and increase the risk of side-effects. In medical terms, this is called as a
Drug Interaction.
Vomistop Tablet interacts with
antidepressants (
citalopram,
escitalopram), which are used to treat
depression. Use of Vomistop with antidepressants may lead to an increased risk of abnormal heartbeat (QT-interval prolongation). Avoid the combined use of Vomistop and antidepressants.
There may be an interaction of
Vomistop with antipsychotics (
haloperidol,
pimozide,
sertindole), which are used to treat mental disorders. When Vomistop is used with antipsychotics drugs, patients are at increased risk of abnormal heartbeat (QT-interval prolongation). The combined use of Vomistop with antipsychotic drugs is not recommended.
Special instructions need to be followed while taking this medicine along with
antibiotics, antifungal agents and antimalarial agents (
erythromycin,
levofloxacin,
moxifloxacin,
spiramycin,
pentamidine,
halofantrine and
lumefantrine), which are used to treat bacterial infections, fungal infections and
malaria. The combined use of Vomistop with antifungal agents,
antibiotics, and antimalarial drugs may lead to an increased risk of abnormal heartbeat (QT-interval prolongation). The combined of Vomistop with these agents is not recommended.
Your doctor's guidelines may need to be followed while taking this medicine along with
apomorphine, which is used to treat Parkinson's disease. Use of apomorphine may potentiate the high blood pressure conditions of Vomistop. Apomorphine can only be used if its benefit outweighs the risks with Vomistop. Patients undergoing apomorphine therapy should start using Vomistop at least 2 days before the treatment. The dose of Vomistop should be adjusted to the lowest effective dose and to be discontinued shortly. Before starting combined treatment of Vomistop with apomorphine, patients should be assessed for the risk factors such as abnormal heartbeats (QT prolongation), heart failure, abnormal function of the
liver or significant
electrolyte disturbance.
Special instructions need to be followed while taking this medicine along with
bepridil,
diphemanil, and
methadone, which are used to treat chest
pain, stomach
ulcer and severe pain due to
cancer respectively. When Vomistop is used with bepridil, diphemanil or methadone, patients are at increased risk of abnormal heartbeat (QT interval prolongation). The combined use of Vomistop with these drugs should be avoided.
Vomistop Tablet interacts with anticancer drugs (
toremifene,
vandetanib,
vincamine), which are used to treat
cancer. Patients who are using anti-cancer drugs along with Vomistop are at increased risk of abnormal heartbeat (QT-interval prolongation). Such patients should not take Vomistop with anti-cancer drugs.
There may be an interaction of
Vomistop with
antihistaminics (
mequitazine,
mizolastine), which are used to treat allergic conditions. Antihistaminics with Vomistop may lead to an increased risk of abnormal heartbeat (QT-interval prolongation). Patients should avoid this combination of Vomistop with antihistaminics.
Vomistop Tablet may interact with stomach or intestinal medicines (
cisapride,
dolasetron,
prucalopride), which are used to treat stomach or intestinal disorders. When Vomistop is used with stomach or intestinal medicines, patients are at increased risk of abnormal heartbeat (QT-interval prolongation). Such patients should avoid the combined use of Vomistop with stomach or intestinal medicines.
Special instructions need to be followed while taking this medicine along with
ketoconazole, which is used to treat fungal infections. The combined use of ketoconazole with Vomistop, may decrease the metabolism of Vomistop and further leads to the abnormal heartbeat (QT prolongation). Take necessary precautions while using the combination of ketoconazole with Vomistop.
Vomistop Tablet interacts with
azithromycin and
roxithromycin, which are used to treat bacterial infections. When Vomistop is used with anti-bacterial drugs, patients may experience an increased risk of abnormal heartbeat (QT-interval prolongation). The use of this combination may cause low blood pressure and low levels of
potassium in the blood. Use of roxithromycin with Vomistop may also increase the level of Vomistop in the blood. Precaution should take necessary precautions while using Vomistop with anti-bacterial drugs.
There may be an interaction of
Vomistop with moderate CYP3A4 inhibitors such as
diltiazem,
verapamil, and macrolides which are used to treat high blood pressure and bacterial infections. The combined use of Vomistop with moderate CYP3A4 inhibitors may increase the level of Vomistop in the blood. Such patients are at an increased risk of abnormal heartbeat (QT-interval prolongation). Such patients should avoid the combined use of Vomistop with these moderate CYP3A4 inhibitors.
Vomistop Tablet may interact with Potent CYP3A4 inhibitors such as
protease inhibitors, systemic azole antifungals (
fluconazole or
voriconazole), macrolides (
erythromycin,
clarithromycin, and
telithromycin), which are used to treat viral, fungal and bacterial infections respectively. When Vomistop is used with potent CYP3A4 inhibitors, may increase the level of Vomistop in blood. The combined use of Vomistop with potent CYP3A4 inhibitors should be avoided.
This page does not contain all the possible interactions of Vomistop Tablet. Share a list of all medicines that you use with your doctor and pharmacist. Do not start, stop, or change the dose of any
medicines without the approval of your doctor.